AFYAConsumer Defensive · Education & Training ServicesThe 9 Wall Street analysts covering Afya Ltd. hold a median 12-month price target of $17 — +14.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 85 of 100 as at 2 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Afya Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (89): Sales and profits are climbing, and climbing faster than before.
Accruals (46): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (41): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on AFYA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +14.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 22 June 2026 | JP Morgan | Maintains | Neutral | $22 → $21 |
| 30 Apr 2026 | JP Morgan | Maintains | Neutral | — |
| 24 Feb 2026 | B of A Securities | Downgrade | Neutral | — |
| 13 Feb 2026 | Morgan Stanley | Downgrade | Underweight | — |
| 16 Jan 2026 | UBS | Downgrade | Neutral | — |
| 8 Jan 2026 | UBS | Maintains | Buy | — |
| 7 Jan 2026 | JP Morgan | Downgrade | Neutral | — |
| 8 Sept 2025 | JP Morgan | Upgrade | Overweight | — |
| 8 Sept 2025 | UBS | Upgrade | Buy | — |
| 29 July 2025 | Citigroup | Upgrade | Neutral | — |
| 12 June 2025 | UBS | Maintains | Neutral | — |
| 11 Mar 2025 | Morgan Stanley | Downgrade | Underweight | — |
| 31 Jan 2025 | Citigroup | Downgrade | Sell | — |
| 17 Jan 2025 | JP Morgan | Maintains | Neutral | — |
| 3 Dec 2024 | Goldman Sachs | Initiates | Sell | — |
| 30 Aug 2024 | UBS | Initiates | Neutral | — |
| 21 June 2024 | Morgan Stanley | Maintains | Equal-Weight | — |
| 22 Jan 2024 | Morgan Stanley | Downgrade | Equal-Weight | — |
| 27 Nov 2023 | JP Morgan | Downgrade | Neutral | — |
| 13 Oct 2023 | Morgan Stanley | Upgrade | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AFYA appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 3 Sept 2026, Afya Ltd. returned +2.2% against +21.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 61% of US stocks
Cheaper than 87% of US stocks
Cheaper than 60% of US stocks
Cheaper than 56% of US stocks
Higher than 41% of US stocks
Higher than 53% of US stocks
Higher than 82% of US stocks
Higher than 87% of US stocks
Higher than 82% of US stocks
Higher than 77% of US stocks
Higher than 89% of US stocks
Higher than 94% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Afya Ltd. has a market value of $1.3B and an enterprise value of $665.3M.
Revenue in the twelve months to 31 Mar 2026: $3.8B. The latest quarter grew 5.7% year on year.
Net income over the same four quarters: $773.2M, a 20.5% net margin.
Free cash flow in the twelve months to 31 Mar 2026: $1.2B, after $140.3M of capital spending.
Afya Ltd. spent $0.0 on dividends in the twelve months to 31 Mar 2026.
Trailing P/E: 8.9×; forward P/E: 7.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 17.59%, paying out 40% of earnings.
Afya Ltd. employs 9,395 people — $402K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Afya Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
On September 2, 2026, Zacks Investment Research added Afya Ltd. (AFYA) to its Zacks Rank #5 (Strong Sell) List, according to the news item "New Strong Sell Stocks for September 2nd."
Why it matters — A Strong Sell ranking from Zacks signals a negative near-term outlook that AFYA watchers would want to be aware of when tracking the stock.
Afya reported 2Q26 results with revenue up 6% year-over-year, barely above inflation, alongside margin contraction and slowing student growth. Regulatory risks from ENAMED exam results persist, despite a temporary injunction lifting some restrictions, while pricing power has weakened with tuition increases now only matching inflation.
Why it matters — AFYA watchers would care because persistent ENAMED regulatory risks threaten both seat capacity and brand reputation, and weakened pricing power undermines the company's premium-pricing thesis for medical seats.
On August 26th, 2026, AFYA was added to the Zacks Rank #5 (Strong Sell) List, along with APTV and CVCO, according to Zacks Investment Research.
Why it matters — AFYA's addition to the Strong Sell list signals that Zacks' quantitative ranking system has assigned AFYA a top bearish outlook among the stocks it covers.
Afya announced that discussions with Yduqs Participações regarding a potential business combination between the two companies are at an early stage, following a material fact disclosure made by Yduqs under Brazilian securities regulations. Both parties stated the talks remain preliminary.
Why it matters — A potential business combination with Yduqs could significantly reshape Afya's corporate structure and competitive position, making this early-stage development of interest to Afya shareholders.
Afya (AFYA) reported Q2 earnings of $0.45 per share, below the Zacks Consensus Estimate of $0.46 per share, though up from $0.40 per share in the same quarter a year ago. Revenues also lagged estimates.
Why it matters — The results lagged analyst expectations for the quarter, which is a notable data point for those tracking AFYA's financial performance.
The 9 Wall Street analysts covering Afya Ltd. have a median 12-month price target of $17, with estimates ranging from $15 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering Afya Ltd., 1 rate it a Buy, 5 a Hold and 3 a Sell. Ticker Nerd's systematic factor model ranks Afya Ltd. 85 out of 100 across roughly 4,600 US stocks as at 2 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 2 Sept 2026, Afya Ltd. ranks 85 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (89 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies +14.5% from the last close, and Ticker Nerd's factor model ranks Afya Ltd. 85 out of 100 as at 2 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Afya Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AFYA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $21 over the next 12 months.
Afya Ltd. returned +2.2% over the 12 months to 3 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Afya Ltd Class A Common Shares represent equity in Afya Ltd, a Brazil-based medical education and healthcare practice solutions company. Afya focuses on an integrated physician-centered platform that supports students and doctors through undergraduate medical education, residency preparation, continuing education, postgraduate programs, and digital practice-management tools.
The most recent item we track (Zacks Investment Research, 2 Sept 2026): "New Strong Sell Stocks for September 2nd". On September 2, 2026, Zacks Investment Research added Afya Ltd. (AFYA) to its Zacks Rank #5 (Strong Sell) List, according to the news item "New Strong Sell Stocks for September 2nd."
Afya Ltd Class A Common Shares represent equity in Afya Ltd, a Brazil-based medical education and healthcare practice solutions company. Afya focuses on an integrated physician-centered platform that supports students and doctors through undergraduate medical education, residency preparation, continuing education, postgraduate programs, and digital practice-management tools. Its business is organized around education services, digital content, residency preparatory and specialization programs, and medical practice solutions, giving it a broad role across the medical training lifecycle. The company serves medical students, practicing physicians, and healthcare professionals seeking educational content and professional support tools. Afya’s Class A common shares are one class of its publicly traded equity and carry standard voting and ownership rights within the company’s share structure.
9,395 employees · Brazil · https://www.afya.com.br
